EICHORCondition: Older Patients · Colorectal Cancer · Metastatic Cancer · Sponsor: Leiden University Medical Center
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized colorectal cancer, with regard to progression-free survival (PFS). The choice between monotherapy (a fluoropyrimidine) and doublet chemotherapy (a fluoropyrimidine with oxaliplatin) will be made for each individual patient based on expected risk of chemotherapy toxicity (according to the G8 screening). Patients classified as low risk of toxicity will be randomized between doublet chemotherapy in either full-dose, or with an upfront dose-reduction of 25%. Patients classified as high risk will be randomized between monotherapy in either full-dose or upfront dose-reduction. Primary outcome is PFS. Secondary endpoints include grade ≥3 toxicity, QoL, physical functioning, overall survival, number of treatment cycles, dose reductions, hospital admissions, cumulative received dosage and cost-effectiveness.
This description comes directly from the study's public registry record.
Joosje Baltussen · 071 - 526 35 23 · DOSAGE@lumc.nl
Data Management: Clinical Research Center LUMC · ClinicalResearchCenter@lumc.nl
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients aged 70 years or older with colorectal cancer and distant metastases without localized treatment options. * Patients who are candidates for first-line palliative chemotherapy as judged by their treating oncologist * Being able to understand the Dutch language * Adequate bone marrow and organ function: Absolute neutrophil count (ANC) \> 1.5 x 10\^9 mmol/L, Hemoglobin (Hb) \> 6.0 mmol/L, Platelets \>100 x 109 / L, Serum bilirubin ≤ 2 x upper limit of normal (ULN), serum transaminases ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver metastases. Exclusion Criteria: * Patients who received prior palliative chemotherapy * Patients in whom local treatment of metastases is scheduled (i.e. liver surgery or stereotactic radiotherapy) * Candidates for triple chemotherapy * Patients who received prior adjuvant chemotherapy in the one year before inclusion in the study (chemotherapy before that time is allowed) * Patients with complete or incomplete dihydropyrimidine dehydrogenase (DPD) deficiency * Patients with Microsatellite instable (MSI)-high colorectal cancer * Patients with HIV or active hepatitis * Patients with severe kidney failure (defined as GFR ≤30ml/min) * Patients with severe cognitive deficits making informed consent not possible
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Jeroen Bosch Ziekenhuis | 's-Hertogenbosch, Netherlands | Not Yet Recruiting |
| Noordwest Ziekenhuisgroep | Alkmaar, Netherlands | Not Yet Recruiting |
| Ziekenhuis Amstelland | Amstelveen, Netherlands | Not Yet Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Not Yet Recruiting |
| Rijnstate | Arnhem, Netherlands | Not Yet Recruiting |
| Wilhelmina Ziekenhuis | Assen, Netherlands | Not Yet Recruiting |
| Rode Kruis Ziekenhuis | Beverwijk, Netherlands | Not Yet Recruiting |
| Slingeland Ziekenhuis | Doetinchem, Netherlands | Not Yet Recruiting |
| Ziekenhuis Gelderse Vallei | Ede, Netherlands | Not Yet Recruiting |
| Catharina Ziekenhuis | Eindhoven, Netherlands | Recruiting |
| Treant | Emmen, Netherlands | Not Yet Recruiting |
| Admiraal de Ruyter Ziekenhuis | Goes, Netherlands | Not Yet Recruiting |
+ 24 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06275958